@LifeNetwork_AI
Account based inSoutheast Asia
About this account
- Account based in
- Southeast Asia
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
The clinical-development coordination layer for AI-generated drugs | Discord: https://nitter.cf/t.co/gOvHPKVGYB | Telegram: https://nitter.cf/t.co/DVjbfueQrk
Joined March 2024
- Tweets1K
- Following355
- Followers62.5K
- Likes625
Pinned Tweet
๐ก๐ฉ๐๐๐๐ ๐๐ง๐ ๐ง๐ฎ๐ถ๐๐ฎ๐ป ๐ฎ๐ฌ๐ฎ๐ฒ - ๐ ๐ฎ๐ฝ๐ฝ๐ถ๐ป๐ด ๐๐ต๐ฒ #๐๐ฒ๐ฎ๐น๐๐ต๐ฐ๐ฎ๐ฟ๐ฒ๐๐ ๐ฉ๐ฎ๐น๐๐ฒ ๐๐ต๐ฎ๐ถ๐ป
At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented โLifeAI Biohub: A Purpose-built AI platform for Drug Developmentโ
One signal emerged throughout the session:
As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders.
๐ง๐ต๐ฒ ๐๐ฒ๐ฎ๐น๐๐ต๐ฐ๐ฎ๐ฟ๐ฒ ๐๐ ๐ฉ๐ฎ๐น๐๐ฒ ๐๐ต๐ฎ๐ถ๐ป
Pharma โ Hospitals โ Doctors โ Labs โ Regulators โ Auditors โ Patients
Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization.
๐๐ถ๐ณ๐ฒ๐๐ ๐๐ถ๐ผ๐๐๐ฏ
Shared Infrastructure โ Coordination Layer โ Connected Network โ Application Success
This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry.
The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale.
It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.
What kind of operational infrastructure does coordination across the healthcare value chain actually require?
Eight years of building clinical programs across Southeast Asia, working with governments, hospital networks, and pharmaceutical companies, produced one consistent finding: the challenge is not the absence of capable AI. It is the absence of operational infrastructure that makes coordination reusable across programs.
Without that infrastructure, coordination remains highly program-specific, especially in drug development, where multiple key players must work together across the development process.
The infrastructure this requires has three properties.
It has to be reusable. Clinical programs should move from bespoke projects to reusable rails, with shared coordination rails replacing bespoke integration at every site.
It has to compound. Every application should strengthen the model, the network, and the protocol, building greater capacity across the ecosystem over time.
It has to enable coordination among independent actors. Hospitals, doctors, labs, pharma sponsors, regulators, patients, and AI builders can contribute services, validation, and clinical execution without surrendering operational sovereignty.
At Life AI, we are building an operating infrastructure for drug development around these requirements, bringing together AI-driven discovery, wet-lab screening, and clinical validation.
Why is validation so difficult to accelerate?
Because unlike discovery, validation cannot be completed in isolation.
An AI-generated drug candidate still has to move through key players across the healthcare value chain, including pharma teams, clinical sites, hospitals, clinicians, patients, and regulators. Each operates with different timelines, evidence requirements, compliance constraints, and operational priorities.
A candidate can move forward on one front while remaining constrained elsewhere, whether by patient recruitment, study execution, evidence generation, or the decisions required to advance it.
This makes validation more operationally complex than discovery. Discovery can be accelerated within a model, platform, or controlled environment, while validation depends on how effectively these key players coordinate and execute across the development process.
With more candidates entering development, that operational complexity compounds, requiring more evidence generation, clinical execution, patient participation, and coordinated decision making across organizations.
As AI accelerates discovery, the need for better coordination and the infrastructure to support it becomes increasingly important downstream.
Why is validation so difficult to accelerate?
Because unlike discovery, validation cannot be completed in isolation.
An AI-generated drug candidate still has to move through key players across the healthcare value chain, including pharma teams, clinical sites, hospitals, clinicians, patients, and regulators. Each operates with different timelines, evidence requirements, compliance constraints, and operational priorities.
A candidate can move forward on one front while remaining constrained elsewhere, whether by patient recruitment, study execution, evidence generation, or the decisions required to advance it.
This makes validation more operationally complex than discovery. Discovery can be accelerated within a model, platform, or controlled environment, while validation depends on how effectively these key players coordinate and execute across the development process.
With more candidates entering development, that operational complexity compounds, requiring more evidence generation, clinical execution, patient participation, and coordinated decision making across organizations.
As AI accelerates discovery, the need for better coordination and the infrastructure to support it becomes increasingly important downstream.
AI is accelerating drug discovery. But the pressure is shifting downstream, toward the work required to validate what discovery produces.
Across science and life sciences, AI is moving deeper into discovery. Anthropic is expanding AI into scientific research, Isomorphic Labs is scaling AI-first drug design and development, and Discovery Loop is building systems to automate experimental loops.
As these capabilities advance, more targets can be explored, more molecules can be designed, and more potential candidates can be generated. The discovery layer is becoming faster and more expansive.
But accelerating discovery does not automatically accelerate the path to validation.
A promising candidate still has to be evaluated, tested, and supported by sufficient evidence before it can move forward. Clinical validation is where this downstream pressure becomes especially visible. The gains from faster discovery can begin to narrow if the path to validation remains slow and difficult to scale.
For Life AI, this raises a critical question: How do we make sure the path to validation can keep pace as AI accelerates discovery?
AI is accelerating drug discovery. But the pressure is shifting downstream, toward the work required to validate what discovery produces.
Across science and life sciences, AI is moving deeper into discovery. Anthropic is expanding AI into scientific research, Isomorphic Labs is scaling AI-first drug design and development, and Discovery Loop is building systems to automate experimental loops.
As these capabilities advance, more targets can be explored, more molecules can be designed, and more potential candidates can be generated. The discovery layer is becoming faster and more expansive.
But accelerating discovery does not automatically accelerate the path to validation.
A promising candidate still has to be evaluated, tested, and supported by sufficient evidence before it can move forward. Clinical validation is where this downstream pressure becomes especially visible. The gains from faster discovery can begin to narrow if the path to validation remains slow and difficult to scale.
For Life AI, this raises a critical question: How do we make sure the path to validation can keep pace as AI accelerates discovery?
LIFE AI retweeted
I used to come to the Google office mostly for the food. This time, it's special. I came here for work.
I just finished a video interview with the Google for Startups team. They asked wonderful questions, and ten minutes was nowhere near enough. Here's what I wish I'd had time to say.
Years ago, I was a Google engineer on the Gmail and Google Data Infra teams. Walking back in as a founder, selected for the first Google for Startups Accelerator: Southeast Asia, feels like a homecoming. Google taught me how to build systems billions depend on. Now I'm bringing that standard to healthcare.
At Life AI, we're building an operating infrastructure for drug development: AI models for drug discovery, a robotic wet lab for in vitro screening, and a network of hospitals for clinical validation. Several products run on it. The one we're bringing to Google is closest to my heart: Life Cloud, an AI-powered cloud for healthcare.
Here's the problem. AI has disrupted industry after industry, but not yet healthcare. Hospital data is uniquely hard: fragmented, buried deep inside departments. Connecting data within one hospital is already a serious challenge. Connecting a network of hospitals is orders of magnitude harder. Yet patients move between hospitals, test by test. The warning sign a doctor needs often already exists, scattered across systems, never connected in time.
Take thalassemia: about 13% of Vietnamese, 14 million people, carry the gene. Every year, around 8,000 affected babies are born, most of them preventable. The first clue hides in a routine blood test that costs less than a cup of coffee, stored somewhere, in some hospital.
Life Cloud is built on one principle: the data never moves. The AI does. Hospitals keep full control of their records. The AI comes to them and learns across the whole system. The AI flags and suggests. The doctor always makes the final decision.
What excites me most is the mentorship. I still remember how much I learned just by sitting close to great engineers at Google. Now my whole team gets three months of that. Honestly, it feels a bit like going back to school.
In October, I'll bring our product to Google San Francisco's bootcamp for engineers to stress-test. Thalassemia doesn't stop at borders. With health partners in Thailand and Indonesia, Southeast Asia is the map we're building for.
Closing the gap between what AI can demonstrate and what doctors can depend on. That's the whole journey. And yes, I'm coming back to Google, not only for food, but for work too.
If you're a clinician, life-science researcher, or investor who cares about trustworthy healthcare AI in Southeast Asia, my inbox is open.
#GoogleForStartups #HealthcareAI #LifeCloud
AI is moving faster than the systems around it. In healthcare, that gap matters.
But what makes that gap so difficult to close?
โHow do we turn AI intelligence into accountable action across fragmented healthcare systems?โ
It is also a question that has increasingly shaped how Life AI thinks about healthcare AI. Speaking at NVIDIA GTC Taiwan 2026, Life AI Co-Founder and CEO Dr. Tuan Cao @tuan_lifeai put it this way:
โIn other industries, if you have the best model, you win. But in healthcare, what actually matters is the coordination of so many key players across the healthcare value chain.
That is why running a clinical trial in the US is so expensive. It costs about $20 million to $100 million to run a Phase III clinical trial, and for every patient, we pay about $500,000 because the man in the middle has to coordinate so many different players: the pharma, the hospital, the patient, and the doctor.
So coordination of all of those key players is actually one of the main bottlenecks.โ
The challenge is not simply advancing AI, but understanding what it takes to make AI work across the complexity of healthcare.
The NVIDIA Inception Grand Challenge 2026 gives Life AI a timely platform to bring this infrastructure question into a broader AI conversation.
1/6
Asia is living longer. But too many of those years are spent in poor health.
That is the central tension explored in a recent Future of Asia Podcast from the McKinsey Health Institute.
So what stands between living longer and living healthier?
๐งต Here are some numbers and insights worth looking at.
4/6
What stands out is that the opportunity is not only about discovering new treatments.
McKinsey points to the potential of proven interventions, particularly those focused on prevention at the population and individual levels.
The challenge becomes how to move prevention earlier, broaden access, and make its impact more consistent.
This is where the conversation shifts:
from healthcare to health.
6/6
And this is the key question left open by the discussion:
When the pieces of a personโs health journey are spread across different interventions, providers, and systems, what connects them over time?
The McKinsey Health Instituteโs From healthcare to health: Asiaโs longevity opportunity is well worth reading for anyone thinking about what comes next for healthcare in the region.
mckinsey.com/featured-insighโฆ
Life AI Named a Top 20 Finalist in the NVIDIA Inception Grand Challenge 2026
Life AI has been named one of the Top 20 Finalists in the NVIDIA Inception Grand Challenge 2026, selected from more than 500 startups across Asia Pacific.
The recognition follows Life AIโs selection in 2025 as one of six startups in the inaugural FastTrack AI Accelerator, powered by GenAI Fund and accelerated by the NVIDIA Inception Program.
On September 22, our co-founder and CEO, Dr. Tuan Cao, will present Life AIโs perspective at the Grand Challenge Finale during NVIDIA AI Day Singapore.
But the significance of this milestone extends beyond the competition.
AI capabilities are advancing at unprecedented speed. Yet in healthcare, building more capable AI is only the beginning. The harder challenge is making that intelligence usable inside systems that were never designed to work together.
Clinical records, workflows, validation processes, and decision-making remain distributed across hospitals, laboratories, pharmaceutical companies, and care teams. Moving AI from isolated pilots into real-world practice therefore requires more than a powerful model. It requires a way to connect signals, coordinate actions, and maintain accountability across those boundaries.
As AI intelligence becomes increasingly abundant, how do we turn it into accountable action across fragmented healthcare systems?
That is the question Life AI is taking to Singapore. In the weeks ahead, we will share how we are approaching it.
The next edge in drug development will come from understanding patients at higher resolution.
For decades, clinical evidence was shaped by scheduled visits. What patients reported. What clinicians observed. Everything between visits remained largely unseen.
The FDAโs Digital Health Technologies program is expanding the use of continuous and frequent measurements beyond traditional study visits, including through wearables, sensors, and remote monitoring.
For drug development, this opens the possibility of following treatment response beyond scheduled assessments and across the patient journey.
But capturing these signals is only part of the challenge.
Biological signals, interventions, and outcomes remain fragmented across the patient journey. Without coordination, the longitudinal picture remains incomplete.
The next infrastructure layer will need to connect these signals with interventions and outcomes across time, institutions, and real-world conditions.
As the FDA advances the regulatory pathway for digitally derived endpoints, that coordination layer becomes increasingly important to drug development.
Source: FDA, Digital Health Technologies for Drug Development fda.gov/science-research/sciโฆ
AI can now generate more drug and treatment candidates than the healthcare industry can ever validate.
That gap between what AI can discover and what actually reaches patients is the problem Life AI was built to close.
What we're most excited about in the @GoogleStartups Accelerator: Southeast Asia program is the chance to work directly with Google's engineering teams on scaling that infrastructure, the rails that help hospitals and pharma partners move healthcare AI programs from pilot to real, deployed care.
We've already seen what's possible when this works: programs that used to take years now take months, at a fraction of the cost, while still meeting regulatory standards.
Over the next three months, we'll be pressure testing our technology alongside some of the best AI minds in the industry, building toward a technical residency in San Francisco.
More soon.
#AcceleratedWithGoogle
We're pleased to announce that Life AI has been selected for the @GoogleStartups Accelerator: Southeast Asia program.
We look forward to the opportunities ahead and to sharing our journey.
[goo.gle/4wIlbsP] #AcceleratedWithGoogle
AI in drug development is entering a more demanding phase.
As candidates move through the development pipeline, they face increasingly complex challenges across biological validation, translational risk, patient heterogeneity, and the timing of evidence.
Many candidates enter the pipeline. Far fewer progress toward clinical validation.
The next frontier is not simply increasing the number of candidates.
It is generating robust, validated, decision ready evidence earlier in the development process, enabling more informed decisions at critical stages.
The list is yours to fill.
Whatโs the one self-care habit youโre committing to this weekend?
Drop it below. You might inspire someone to finally do it too. ๐
We're pleased to announce that Life AI has been selected for the @GoogleStartups Accelerator: Southeast Asia program.
We look forward to the opportunities ahead and to sharing our journey.
[goo.gle/4wIlbsP] #AcceleratedWithGoogle
Welcome to the startups joining the Google for Startups Accelerator: SEA 2026!
Over the next three months, they'll build and scale AI models before heading to SFO for their first-ever US technical residency. ๐
Meet the cohort โก๏ธ goo.gle/4wIlbsP
AI in drug development is moving beyond isolated use cases and becoming a portfolio of decision support capabilities across the full development lifecycle.
In discovery, AI supports target identification, molecule design, screening, and lead optimization.
In nonclinical development, AI supports toxicity assessment, pharmacology modeling, and translational risk analysis.
In clinical development, AI supports patient stratification, trial feasibility, endpoint selection, dose optimization, and safety monitoring.
In postmarketing, AI supports real world data analytics, signal detection, subgroup analysis, and long term treatment performance.
In manufacturing, AI supports process monitoring, quality control, and production consistency.
The strategic opportunity is not to apply AI more broadly for its own sake. It is to apply AI where uncertainty is highest and decisions are most consequential, where better evidence earlier can improve validation, reduce development risk, and strengthen the basis for advancing the right therapies toward patients.
That is the standard by which AI in drug development will increasingly be measured.
AI is becoming an increasingly integrated part of drug development.
The FDAโs Center for Drug Evaluation and Research (CDER) has observed growing use of AI across the drug product lifecycle, including nonclinical, clinical, manufacturing, and postmarketing activities.
The scale is already significant.
Between 2016 and 2023, CDER gained experience with more than 500 submissions containing AI components. This experience helped inform the FDAโs 2025 draft guidance on the use of AI to support regulatory decision making.
For pharma and biotech, this signals a broader shift.
AI-enabled drug development is moving beyond individual discovery applications. It is increasingly being applied to the information and data that support development and regulatory decisions.
That also raises the requirements for how these systems are developed and evaluated.
Key considerations include context of use, risk-based validation, data governance, performance assessment, documentation, and lifecycle management.
The next phase of AI in drug development will be measured by more than speed.
It will be measured by the credibility, traceability, and confidence of the evidence AI helps generate for development and regulatory decisions.
Sources:
FDA โ Artificial Intelligence for Drug Development: fda.gov/about-fda/center-druโฆ
FDA โ Considerations for the Use of AI to Support Regulatory Decision-Making: fda.gov/regulatory-informatiโฆ
